Losardex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Losardex

Property Description
Active Ingredient Losartan potassium
Form Oral tablet (Film-coated)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose Antihypertensive agent
Origin Synthetic compound

The Identity and Classification of Losardex

Losardex is a widely utilized prescription-only medicine whose identity is defined by its core active substance, Losartan potassium. The drug belongs to the class of cardiovascular medications known as Angiotensin II Receptor Blockers (ARBs), a category clinically recognized for its systemic impact on vascular resistance.

The active compound, Losartan, is a non-peptide, synthetic compound that functions as a selective AT₁ receptor antagonist. This means Losardex is engineered to selectively bind to and block the Type 1 Angiotensin II receptors in the body, distinguishing it from other antihypertensive agents by its unique point of intervention in the complex process of vascular regulation.

Form, Composition, and General Purpose

Losardex is consistently supplied as an oral tablet for oral administration, designed to ensure stable delivery of the active substance for systemic action. It is a single-active-substance product, meaning its therapeutic effect stems solely from the Losartan potassium component alongside pharmaceutical excipients.

As an antihypertensive agent, the general purpose of Losardex is to achieve a sustained lowering of blood pressure. Losartan helps reduce the force exerted against blood vessel walls. By blocking the action of Angiotensin II, Losardex prevents the signaling that causes blood vessel tightening, consequently promoting vasodilation (vessel relaxation). This systematic reduction in peripheral vascular resistance provides the primary benefit of managing high blood pressure and reducing strain on the cardiovascular system.

Regulatory References

  1. DailyMed (NIH/NLM)

What side effects are possible with Losardex?

Losardex (losartan) is associated with several adverse reactions and safety restrictions documented in official government regulatory information, which guide its careful use.

Key Adverse Reactions and Frequencies

Adverse reactions classified by frequency of occurrence include:

  • Common: Dizziness, upper respiratory infection, nasal congestion, back pain, fatigue, and diarrhea.
  • Rare: Angioedema, a serious hypersensitivity reaction involving swelling of the face, lips, throat, and tongue.

Serious Safety Considerations

The most serious regulatory restriction is a Boxed Warning concerning fetal toxicity. Use of Losardex during the second and third trimesters of pregnancy can cause injury and death to the developing fetus, including skull hypoplasia, anuria, and renal failure. The medicine is contraindicated during these periods and must be discontinued immediately upon detection of pregnancy.

Clinically significant adverse reactions requiring specific monitoring include:

  • Hypotension: A significant drop in blood pressure, especially in patients who are volume- or salt-depleted.
  • Hyperkalemia: Elevated potassium levels, which can be serious and may necessitate periodic blood testing.
  • Renal Function Deterioration: Changes in kidney function, including acute renal failure, particularly in susceptible patients like those with severe heart failure or renal artery stenosis. Periodic monitoring of renal function and serum potassium is specified in regulatory labeling.

Population and Quality Restrictions

Losardex is contraindicated for coadministration with aliskiren in patients with diabetes. Lower starting doses are recommended for patients with a history of hepatic impairment. Additionally, past regulatory actions include voluntary product recalls for certain batches of losartan due to the detection of unacceptable levels of nitrosamine impurities, which are classified as probable human carcinogens.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that overdosage with Losardex (Losartan potassium) is primarily characterized by severe effects on the cardiovascular system. The most likely presentation is hypotension (excessively low blood pressure), which carries the risk of progressing to profound hypotension requiring urgent care. Changes in heart rhythm may also occur, documented as tachycardia (abnormally fast rate) or the potential for bradycardia (abnormally slow rate).

Mandatory Emergency Actions

In all cases of suspected overdosage, the government-mandated guidance is to seek immediate medical attention. This requires contacting emergency medical services or a designated Poison Control Center right away, as stated in the official prescribing information. Close observation and monitoring of the patient's hemodynamic status are required during management.

Supportive Care and Limitations

The management strategy is limited to symptomatic and supportive treatment because no specific antidote is known to reverse the effects of Losartan. Furthermore, official labeling specifies that Losartan and its active metabolite are not removed by hemodialysis, which defines a constraint on procedural intervention. A population-specific note requires that neonates exposed in utero be monitored for hypotension, hyperkalemia, and oliguria.

Therapeutic Uses of Losardex

What Losardex Treats: Main Uses and Benefits

Losardex is primarily utilized for supportive management across various clinical scenarios, relevant when supportive symptom management is appropriate. Its therapeutic applications are considered relevant in conditions such as essential hypertension, treatment of certain renal diseases, and application in conditions such as chronic heart failure.


Easing Symptoms That Interfere with Daily Life

This domain covers conditions associated with acute or disruptive episodes where certain distressing symptoms may become intense or disruptive. Losardex is commonly used to help manage symptoms related to systemic imbalance or heightened physiological activity. It offers symptomatic relief when symptoms interfere with routine activities and contributes to improved comfort during periods of heightened symptoms. This application aligns with the principle: “used in areas where short-term symptom management is appropriate.”

Supportive Management for Fluctuating Symptom Patterns

Losardex is considered relevant in conditions involving episodic or fluctuating manifestations, particularly those characterized by periods of heightened symptoms. It is applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden. This assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Imbalance


Providing Relief During Episodes of Heightened Discomfort

Often used when symptoms intensify and supportive relief is needed, Losardex is relevant in clinical settings marked by increased discomfort or tension. It supports the patient during difficult episodes by easing distress, contributing to easing the overall symptom load, and supporting patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Losardex — official regulatory information

The eligibility profile for Losartan potassium (Losardex) is strictly defined by government regulatory documents, which establish mandated exclusions, conditional use requirements, and established use populations.


Eligibility Scope

Classification Population/Condition Restriction Detail (Official Wording)
Contraindicated Pregnancy (2nd and 3rd Trimesters) Use is contraindicated due to risk of fetal injury and death.
Contraindicated Severe Hepatic Impairment Use is contraindicated as therapeutic experience is lacking.
Contraindicated Hypersensitivity Contraindicated in patients with a known allergy to Losartan or product components.
Contraindicated Aliskiren Concomitant Use Contraindicated in patients with Diabetes Mellitus or renal impairment (GFR < 60 mL/min/1.73 m²) who are taking Aliskiren.

Age and Conditional Use Rules

  • Established Use: Use is established in adults and in pediatric patients aged 6 to 18 years for hypertension [FDA].
  • Not Recommended: The medicine is not recommended for use in children under 6 years of age or in pediatric patients with an eGFR less than 30 mL/min/1.73 m².
  • Conditional Use: Patients with mild-to-moderate hepatic impairment require a lower starting dose. Volume-depleted patients should have their fluid/salt depletion corrected prior to administration.
  • Pregnancy/Lactation: Use is not recommended during the first trimester of pregnancy or while breastfeeding.

Connection to the Overall Eligibility Profile

Official regulatory documents define eligibility by establishing absolute bans, such as the contraindication during later-stage pregnancy, and in patients with severe liver dysfunction. For other populations, eligibility is defined by restrictions based on organ function (e.g., conditional use in mild-to-moderate hepatic impairment) and age (e.g., not recommended for children under six), strictly outlining who can and cannot use the medicine according to governmental labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Losardex, which contains losartan potassium, has formally documented interactions related primarily to its pharmacodynamic effects on potassium and blood pressure, as well as specific pharmacokinetic alterations.

Official Interaction Statements

Classification Interacting Agents Regulatory Description of Outcome
Contraindicated Aliskiren Co-administration is formally contraindicated in patients with diabetes mellitus due to increased risks of hypotension, hyperkalemia, and decreased renal function.
Not Recommended ACE Inhibitors Dual blockade of the renin-angiotensin system (RAS) is not recommended due to increased incidence of renal impairment, hypotension, and hyperkalemia.
Not Recommended Potassium-Sparing Diuretics (e.g., triamterene) & Potassium Supplements The additive effect on serum potassium increases the risk of hyperkalemia; this combination is officially discouraged.
Clinically Significant Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce Losardex’s antihypertensive effects and increase the risk of deterioration of renal function.
Clinically Significant Lithium Decreases the renal clearance of lithium, which results in increased lithium blood levels and potential toxicity.
Pharmacokinetic CYP2C9 Inhibitors (e.g., Fluconazole) Inhibition of the CYP2C9 metabolic pathway reduces the exposure of Losartan's active metabolite (E-3174).

Population-Specific Constraints

Interaction-related risks are heightened or restricted in specific patient groups. The co-administration of Losartan with Hydrochlorothiazide is formally contraindicated in patients with severe hepatic impairment. Additionally, the risk of adverse effects from interactions like those with NSAIDs is greater in volume- or salt-depleted patients.

Mechanism of Action

How Losardex Works: Mechanism of Action


Blocking the AT1 Receptor (Angiotensin II Blockade)

Losardex acts as a selective, competitive antagonist primarily targeting the Angiotensin II type 1 ( AT1) receptor, which is expressed on the surface of vascular smooth muscle, cardiac, and renal cells. The drug and its active metabolite occupy this receptor, thereby preventing the signaling molecule Angiotensin II ( AngII) from initiating its effects, which interferes with a primary regulatory system involved in vasoconstriction and fluid retention.


Modulating the RAAS Cascade and Vascular Tone

This mechanism primarily modulates the Renin-Angiotensin-Aldosterone System (RAAS), a hormonal cascade that influences vascular tone and fluid balance. Interrupting the AngII/ AT1 signaling sequence restricts the immediate downstream consequences, most notably preventing vasoconstriction (narrowing of blood vessels) and reducing aldosterone secretion. This systemic effect produces the physiological changes of vasodilation and reduced systemic vascular resistance.


Influence on Tissue Signaling and Structural Changes

Beyond immediate hemodynamic effects, AT1 blockade also modulates molecular pathways that influence long-term structural changes, such as those related to hypertrophy (cell growth) and fibrosis (scarring) in the heart and kidneys. This mechanistic domain influences factors like TGF-beta signaling and pathways associated with cellular remodeling.

Dosage and Administration Information

Losardex (Losartan potassium) is administered exclusively via the oral route, primarily as a film-coated tablet in strengths of 25 mg, 50 mg, or 100 mg. The standard treatment regimen involves once-daily dosing for all approved indications. The tablets may be taken with or without food.

The initial dosage is formally structured based on the specific clinical scenario. For most adult patients being treated for hypertension, the standard starting dose is 50 mg once daily. However, a lower starting dose of 25 mg once daily is specified for patients who have volume depletion or those with mild-to-moderate hepatic impairment.

Dosage adjustment is a key procedural step, permitting upward titration based on clinical response. The dose can be increased up to a maximum of 100 mg once daily for hypertension. In regimens for chronic heart failure, the initial dose is lower (12.5 mg) and can be titrated weekly up to a maximum of 150 mg.

For pediatric patients (aged 6 to 16 years) with hypertension, the dose is weight-based, starting at 0.7 mg/ kg once daily, with a maximum limit of 50 mg per day. The 50 mg tablet is scored, allowing it to be divided for accurate administration of smaller doses. If a scheduled dose is missed, the next dose should not be doubled. The full therapeutic effect is typically established after three to six weeks of continuous therapy.

Recent Clinical Evidence

Losardex: Recent Clinical Evidence

The research base for Losardex primarily consists of Randomized Controlled Trials (RCTs) and long-term observational studies, adhering to regulatory standards for establishing clinical utility. The medicine was evaluated across three main therapeutic areas.


Evidence for Use in Managing High Blood Pressure

Research exploring the use of Losardex in adults with high blood pressure involved short-term RCTs that measured changes in systolic and diastolic blood pressure. Longer research examined whether its use was associated with changes in the frequency of cardiovascular events, such as stroke. Studies tracked different dose levels and frequently monitored cohorts where target blood pressure levels were observed. Research describes that observed changes in blood pressure varied across certain patient groups.


Evidence for Use in Treating Certain Kidney Diseases

For treating Certain Kidney Diseases (Diabetic Nephropathy), the evidence rests on long-term, placebo-controlled trials. These studies were designed to monitor outcomes related to disease progression in adults with Type 2 Diabetes. Researchers tracked a composite measure, including the time until a patient reached a predefined point related to the doubling of serum creatinine and progression to End-Stage Renal Disease (ESRD). Data for non-diabetic kidney disease remain insufficient.


Evidence for Use in Chronic Heart Failure

Research related to Chronic Heart Failure primarily focused on populations who reported they were unable to tolerate existing first-line therapies. Studies explored the time to all-cause mortality and hospitalization associated with heart failure. Findings were mixed, with certain comparisons against active standard treatments reporting that data related to all-cause mortality were uncertain between the two groups for the primary endpoint.


Research Gaps and Uncertainty

Results apply only to the populations studied. Comparative evidence is lacking against all newer medications, and long-term effects beyond the trial window are not fully established. Older adults were observed in major trials, but data for certain complex subgroups and pediatric patients remain limited.

Key Studies & References

  1. Losartan Drug Information
  2. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study
  3. Heart Failure Endpoint Evaluation of the Angiotensin II Antagonist Losartan (HEAAL) Trial

Frequently Asked Questions (FAQ)

Common questions about Losardex (FAQ)


Q: Is Losardex the same as other 'sartan' drugs like irbesartan or valsartan?

A: Losardex (losartan) belongs to a group of medications known as Angiotensin II Receptor Blockers (ARBs), which includes other drugs like irbesartan and valsartan. According to regulatory documents, all ARBs work similarly by targeting the Angiotensin II type 1 ( AT1) receptor to help relax blood vessels and lower blood pressure.

Q: Is it normal to feel dizzy or lightheaded when first starting Losardex?

A: Yes, dizziness is listed as a common adverse reaction in official product information. Losardex works by lowering blood pressure, and a drop in pressure (hypotension) can cause lightheadedness or dizziness, especially when beginning treatment. If any side effect is concerning, it should be discussed with a healthcare professional.

Q: Are there any major food or drink restrictions when taking Losardex?

A: Official regulatory documents state that Losardex tablets may be taken with or without food. However, a key consideration is that the use of potassium supplements or salt substitutes should be discussed with your healthcare provider, as combining them with Losardex increases the risk of high potassium levels (hyperkalemia).

Q: Can Losardex affect my kidney function or liver enzymes?

A: Yes, Losardex can cause a deterioration of renal function (kidney function), and periodic monitoring of these functions is often part of the treatment plan. Furthermore, regulatory labels caution that Losardex is contraindicated (should not be used) in people with severe hepatic impairment, and lower starting doses are suggested in regulatory guidance for individuals with mild-to-moderate hepatic impairment.

Q: What types of over-the-counter supplements might interact with Losardex?

A: The official drug label lists interactions with several common over-the-counter agents. These include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which are common pain relievers, and supplements that contain high levels of potassium.

Q: Does Losardex have a warning about potassium levels?

A: Yes, official regulatory labeling includes warnings about the risk of Hyperkalemia (elevated potassium levels). Because this condition can be serious, official labeling notes that periodic blood tests to monitor serum potassium levels are often recommended.

Q: Are headaches a common side effect of Losardex when starting out?

A: Headaches are listed as a common side effect in some adverse event profiles for losartan. While the official documents do not specifically link this to the starting period, any new medication may cause temporary side effects as the body adjusts.

Q: Can Losardex cause weight gain or weight loss?

A: General weight change is not typically listed as a common adverse reaction in regulatory documents. However, official information does list edema or swelling (fluid retention) as a potential side effect, which can sometimes be associated with a change in body weight.

Q: How long does Losardex stay in your system after taking a dose?

A: Official pharmacokinetic data indicates that the active drug component, losartan, has a short terminal half-life of about 2 hours. However, its active metabolite (the part that performs most of the work) has a longer terminal half-life of approximately 6 to 9 hours.

Q: Why is Losardex sometimes given with a diuretic ('water pill')?

A: Losardex is often prescribed in combination with a diuretic to provide a greater and more comprehensive blood pressure lowering effect. This combination is commonly used to treat hypertension (high blood pressure) when Losardex alone is insufficient.

Q: Are there long-term side effects of Losardex that develop after years of use?

A: Official information is gathered from long-term clinical trials and ongoing safety monitoring. The regulatory label lists common and rare side effects, but it does not specifically categorize effects as only 'long-term' versus 'short-term' based on duration of use.

Q: Are there specific times of day that are best for taking Losardex?

A: Regulatory documents state that Losardex is a once-daily medication. The label does not mandate a particular time of day for administration, allowing it to be taken when it best fits your daily routine.

Q: Is a persistent cough a known side effect of Losardex?

A: Official regulatory data on Losardex does not list persistent cough as a common side effect. While cough has been reported in post-marketing experience, the frequency of occurrence is not definitively known.

Q: How often do people need to have blood tests while on Losardex?

A: Official regulatory information specifies that periodic monitoring of kidney function and serum potassium levels is required while on this medication. The label specifies that monitoring should be periodic, but does not provide a fixed, universal schedule.

Q: Is Losardex a blood thinner?

A: No, Losardex is not a blood thinner. It belongs to the Angiotensin II Receptor Blocker (ARB) class of medications. Its purpose is to help blood vessels relax and widen, which lowers blood pressure, rather than preventing blood clots.

Q: What are the signs of an allergic reaction to Losardex I should watch for?

A: The most serious allergic reaction associated with Losardex is Angioedema, which is listed in the official post-marketing safety data. Patients are advised to be aware of signs such as swelling of the face, lips, tongue, or throat.

Q: Does Losardex affect blood sugar?

A: Losardex is indicated for use in people with Type 2 diabetes to protect the kidneys. While some clinical studies did not show major changes in fasting blood sugar, monitoring blood sugar may be advised, especially if Losardex is taken in combination with a diuretic.

Q: Can Losardex interact with cold and flu medications?

A: Yes, caution is advised. Many cold and flu medicines contain NSAIDs (like ibuprofen), which can interact with Losardex. Additionally, some decongestants may contain ingredients that can potentially affect blood pressure control.

Q: Is Losardex safe for women of childbearing age?

A: Official guidelines recommend that women of childbearing age discuss the risks with a healthcare provider. Regulatory documents strongly advise against using Losardex during the first trimester of pregnancy and contraindicate its use during the second and third trimesters due to the risk of fetal injury and death.

Q: What is the general success rate of Losardex for controlling hypertension?

A: Official regulatory documents confirm that Losardex is effective at lowering blood pressure, with clinical trials showing measurable mean decreases in both systolic and diastolic pressure. However, a single 'general success rate' percentage for all patients is not provided in the label, as individual response can vary.

Q: Do I need to change my diet while taking Losardex?

A: The primary dietary consideration noted in regulatory information is the use of potassium supplements and salt substitutes containing potassium. Taking these alongside Losardex may cause potassium levels to become too high.

Q: Is Losardex used for anything other than cardiovascular conditions?

A: Yes, Losardex is officially indicated for the treatment of diabetic nephropathy (a form of kidney disease) in patients with Type 2 diabetes who also have a history of high blood pressure. This highlights its specific benefit for kidney protection.

Q: What is the average time Losardex takes to reach its maximum blood pressure lowering effect?

A: The official product information states that the full therapeutic blood pressure lowering effect of Losardex is typically established after three to six weeks of continuous therapy.

Q: Does Losardex cause skin sensitivity to the sun?

A: Safety data reports that photosensitivity (increased skin sensitivity to sunlight) is an adverse event that has been reported. Official regulatory documents generally classify this type of reaction as uncommon or not known in frequency.

How should Losardex be stored and disposed of?

Losardex Storage and Disposal Requirements

Losardex (losartan potassium) tablets must be stored according to strict regulatory conditions to ensure stability and safety.

Storage/Handling Requirement Official Stipulation
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C (59 F to 86 F).
Protection Keep the product away from excess heat, light, and moisture in its tightly closed, original container.
Child Safety Mandatory to keep the medicine out of the sight and reach of children.
Disposal Unused or expired product must be disposed of in accordance with local requirements; avoid throwing into household waste or wastewater.
Liquid Form Stability Compounded oral suspension requires refrigeration (2 C to 8 C) and is stable for up to 4 weeks.

Official labeling requires storage within the specified room temperature range and protection from environmental factors like light and moisture. Disposal instructions mandate following local regulations and prohibit discarding the medicine in wastewater to ensure proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Losardex found in:

A-Z Index: